Liquidia’s early momentum in its inhaled lung medicine may fade if doctor interest levels off, while heavy reliance on one product leaves little room for mistakes. Add in the risk of patent fights in the same drug family, and the long-term outlook could look very different than today’s excitement suggests.Read more
Liquidia is betting that its inhaled therapy YUTREPIA can quickly become a go-to option for people with serious lung blood pressure and other lung diseases, with more uses over time that could unlock a much larger customer base. But a legal fight with a major rival and the risks of relying on one main product could still derail that growth story.Read more
Liquidia’s new inhaled treatment for pulmonary hypertension is seeing fast early use, and improving insurance coverage could turn that momentum into steadier sales. But a big factory expansion and a second medicine still in development mean the long-term story depends on demand holding up and future results staying supportive.Read more
No trending discussion available.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
